The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- GlaxoSmithKline vs. Sanofi: Which Is The Better Dividend Stock?
- Another Good Reason to Buy This Marijuana Stock?
- 3 Reasons You Can Buy This Marijuana Stock
- Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
- Government Delays Medical Marijuana Drug: What It Means for this Marijuana Stock
- 3 Stocks I'll Buy if the Market Crashes